Fecal Microbiota Transplantation With Immune Checkpoint Inhibitors in Lung Cancer

Recruiting Phase 2 Interventional Study
Metastatic Lung Cancer
No Placebo Group Every participant receives an active treatment — no one gets a placebo. Prior Safety Data This treatment has already been tested in at least one earlier human trial.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Trial phase
Phase 2
Study type
Interventional
Purpose
Treatment
Participants needed
80 (estimated)
Sponsor
Soroka University Medical Center · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Immunotherapy has recently become a main-stream treatment option in cancer care, with improved clinical outcomes in many malignancies, especially that of lung cancer. The long-term benefits of this treatment however are limited. There is therefore a critical need to distinguish predictive biomarkers of response from those of resistance, and to develop synergistic strategies for improved therapeuti…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Patient (Recipient) Inclusion Criteria: 1. A histologically confirmed diagnosis of malignancy. 2. Patients over the age of 18. 3. Patients planning to be treated with chemotherapy, immune checkpoint inhibitors and/or targeted therapy. 4. Eastern Cooperative Oncology Group (ECOG) Performance Status …
Contacts

Ismaell Massalha, M.D.

+972526995934

ismaell@post.bgu.ac.il

CONTACT

Amichay Meirovitz, Prof.

+972528805922

amichaym@gmail.com

CONTACT